These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32415892)

  • 21. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
    van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
    Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Floros KV; Cai J; Jacob S; Kurupi R; Fairchild CK; Shende M; Coon CM; Powell KM; Belvin BR; Hu B; Puchalapalli M; Ramamoorthy S; Swift K; Lewis JP; Dozmorov MG; Glod J; Koblinski JE; Boikos SA; Faber AC
    Cancer Res; 2021 Apr; 81(7):1896-1908. PubMed ID: 33483374
    [No Abstract]   [Full Text] [Related]  

  • 23. The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner.
    Mazar J; Gordon C; Naga V; Westmoreland TJ
    Anticancer Agents Med Chem; 2020; 20(13):1613-1625. PubMed ID: 32329693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma.
    Hungate EA; Applebaum MA; Skol AD; Vaksman Z; Diamond M; McDaniel L; Volchenboum SL; Stranger BE; Maris JM; Diskin SJ; Onel K; Cohn SL
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 29117357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells.
    Gu L; Chu P; Lingeman R; McDaniel H; Kechichian S; Hickey RJ; Liu Z; Yuan YC; Sandoval JA; Fields GB; Malkas LH
    EBioMedicine; 2015 Dec; 2(12):1923-31. PubMed ID: 26844271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
    Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
    Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
    Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycine decarboxylase is a transcriptional target of MYCN required for neuroblastoma cell proliferation and tumorigenicity.
    Alptekin A; Ye B; Yu Y; Poole CJ; van Riggelen J; Zha Y; Ding HF
    Oncogene; 2019 Dec; 38(50):7504-7520. PubMed ID: 31444411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathways.
    Bojko J; Kollareddy M; Szemes M; Bellamy J; Poon E; Moukachar A; Legge D; Vincent EE; Jones N; Malik S; Greenhough A; Paterson A; Park JH; Gallacher K; Chesler L; Malik K
    Cancer Lett; 2024 Nov; 604():217263. PubMed ID: 39313128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.
    Cortés C; Kozma SC; Tauler A; Ambrosio S
    Cell Oncol (Dordr); 2015 Oct; 38(5):341-52. PubMed ID: 26306783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
    Chen L; Alexe G; Dharia NV; Ross L; Iniguez AB; Conway AS; Wang EJ; Veschi V; Lam N; Qi J; Gustafson WC; Nasholm N; Vazquez F; Weir BA; Cowley GS; Ali LD; Pantel S; Jiang G; Harrington WF; Lee Y; Goodale A; Lubonja R; Krill-Burger JM; Meyers RM; Tsherniak A; Root DE; Bradner JE; Golub TR; Roberts CW; Hahn WC; Weiss WA; Thiele CJ; Stegmaier K
    J Clin Invest; 2018 Jan; 128(1):446-462. PubMed ID: 29202477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.
    Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ
    Oncotarget; 2015 Jun; 6(17):15510-23. PubMed ID: 25860940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA damage and homologous recombination signaling induced by thymidylate deprivation.
    Yang Z; Waldman AS; Wyatt MD
    Biochem Pharmacol; 2008 Oct; 76(8):987-96. PubMed ID: 18773878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma.
    Agarwal P; Glowacka A; Mahmoud L; Bazzar W; Larsson LG; Alzrigat M
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed.
    Graham-Cole CL; Thomas HD; Taylor GA; Newell DR; Melton RG; Hesp R; Boddy AV
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):197-206. PubMed ID: 16721548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
    Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia-Dependent Expression of TG2 Isoforms in Neuroblastoma Cells as Consequence of Different MYCN Amplification Status.
    Currò M; Ferlazzo N; Giunta ML; Montalto AS; Russo T; Arena S; Impellizzeri P; Caccamo D; Romeo C; Ientile R
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus.
    McGuire TR; Coulter DW; Bai D; Sughroue JA; Li J; Yang Z; Qiao Z; Liu Y; Murry DJ; Chhonker YS; McIntyre EM; Alexander G; Sharp JG; Li R
    BMC Cancer; 2019 Aug; 19(1):837. PubMed ID: 31455317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
    Marrano P; Irwin MS; Thorner PS
    Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity.
    Peirce SK; Findley HW
    Oncol Rep; 2009 Dec; 22(6):1443-9. PubMed ID: 19885598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.